Back to Search
Start Over
Torsemide in Edema Associated with Hepatic Impairment.
- Source :
-
The Journal of the Association of Physicians of India [J Assoc Physicians India] 2024 Sep; Vol. 72 (9S), pp. 32-34. - Publication Year :
- 2024
-
Abstract
- Hepatic edema is caused by decreased hepatic protein synthesis, a consequence of decompensated liver cirrhosis. Fluid accumulation occurs when there is an increase in hydrostatic pressure in the hepatic sinusoids and splanchnic capillaries, as well as low albumin. The first-line treatment for cirrhosis-related ascites is an aldosterone antagonist (spironolactone); however, in severe and recurring ascites, a combination of aldosterone antagonists and loop diuretics (torsemide, furosemide, and bumetanide) is preferable. Torsemide outperformed furosemide in terms of natriuretic and diuretic effects at an equivalent dose. Pharmacological features of torsemide, such as lesser hypokalemia effect, longer duration of action, higher bioavailability, and extended half-life, make it a better alternative than furosemide. In clinical studies, it is considered a safer and more acceptable choice with fewer complications.<br /> (© Journal of the Association of Physicians of India 2024.)
- Subjects :
- Humans
Ascites etiology
Ascites drug therapy
Edema drug therapy
Edema etiology
Liver Cirrhosis complications
Liver Cirrhosis drug therapy
Torsemide pharmacology
Torsemide therapeutic use
Sodium Potassium Chloride Symporter Inhibitors pharmacology
Sodium Potassium Chloride Symporter Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0004-5772
- Volume :
- 72
- Issue :
- 9S
- Database :
- MEDLINE
- Journal :
- The Journal of the Association of Physicians of India
- Publication Type :
- Academic Journal
- Accession number :
- 39291571
- Full Text :
- https://doi.org/10.59556/japi.72.0675